Arcadia Biosciences Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues: | ||
| Product | $1,255 | $1,232 |
| Total revenues | 1,255 | 1,232 |
| Operating expenses (income): | ||
| Cost of revenues | 820 | 688 |
| Research and development | 272 | 359 |
| Loss (Gain) on sale of property and equipment | 2 | (19) |
| Impairment of property and equipment | 36 | — |
| Selling, general and administrative | 3,189 | 4,071 |
| Total operating expenses | 4,319 | 5,099 |
| Loss from continuing operations | (3,064) | (3,867) |
| Interest income | 45 | 198 |
| Other income, net | 3 | 32 |
| Valuation loss on March 2023 PIPE | — | (6,076) |
| Change in fair value of common stock warrant and option liabilities | 593 | 940 |
| Issuance and offering costs allocated to liability classified options | — | (430) |
| Net loss from continuing operations | (2,423) | (9,203) |
| Net loss from discontinued operations | — | (181) |
| Net loss attributable to common stockholders | $(2,423) | $(9,384) |
| Net loss per share attributable to common stockholders: | ||
| Basic and diluted from continuing operations | $(1.78) | $(10.65) |
| Basic and diluted from discontinued operations | $— | $(0.21) |
| Net loss per basic and diluted share attributable to common stockholders | $(1.78) | $(10.86) |
| Weighted-average number of shares used in per share calculations: | ||
| Basic and diluted | 1,361,657 | 864,391 |
| Other comprehensive income, net of tax | ||
| Unrealized gains on available-for-sale securities | $60 | $— |
| Other comprehensive income | $60 | $— |
| Comprehensive loss attributable to common stockholders | $(2,363) | $(9,384) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.